For over 10 years, Lifeline Cell Technology has produced some of the world’s best normal human endothelial cells and normal human fibroblast cells. Additionally, we have developed low serum, serum-free, or xeno-free media, individually optimized for culturing each of these cell types. Now, we are expanding our repertoire and introducing two new additions to our catalog of normal human cell culture products: our Cardiac Microvascular Endothelial Cells and Cardiac Fibroblasts. Our new Cardiac Microvascular Endothelial Cells are optimized for growth in VascuLife® Mv medium and Cardiac Fibroblasts are optimized for growth in our FibroLife® medium.
Our products have been used successfully in research studies to study many normal processes, as well as disease states. In particular, our Fibroblasts and FibroLife® medium have been cited in over 30 publications, and our Large Vessel and Microvascular Endothelial Cells and VascuLife® medium have been cited in over 60 publications.
In addition, our Microvascular Endothelial Cell culture media (VascuLife® VEGF-Mv and VascuLife® EnGS-Mv) have been used to culture different types of microvascular endothelial cells, including mouse cardiac microvascular endothelial cells, as described in the study below.
Lifeline® VascuLife® Culture Media: Supporting Microvascular Endothelial Cell Growth
Hypoxia-inducible factor (HIF)-1 and -2 regulate cellular responses to low oxygen conditions, known as hypoxia. When cells experience hypoxia, HIF proteins are stabilized and induce a transcriptional response that activates multiple pathways, including angiogenesis, the formation of blood vessels. HIF-1 and HIF-2 are composed of two subunits: a and b. The b subunit is shared between the two isoforms and is also known as Aryl hydrocarbon Receptor Nuclear Translocator, or ARNT. In a 2012 study, Han and colleagues isolated pulmonary and cardiac endothelial cells from mice lacking ARNT and cultured them in Lifeline® VascuLife® medium. They found that in response to hypoxic conditions, endothelial cells lacking ARNT did not transcriptionally upregulate hypoxia response genes, and did not migrate or form new vessel branch networks, as compared to control cells with intact ARNT. Furthermore, the authors found that ARNT-null vascular endothelial cells were unable to proliferate and survive under hypoxia or high reactive oxygen species (ROS) conditions, demonstrating that ARNT is critical for HIF-mediated cellular survival in response to hypoxia. Finally, this study demonstrates that primary murine cardiac endothelial cells can be efficiently maintained in Lifeline® VascuLife® medium.
Our new Lifeline® Cardiac cells and optimized media include:
- Human Cardiac Microvascular Endothelial Cells
- VascuLife® VEGF-Mv Microvascular Endothelial Cell medium
- VascuLife® EnGS-Mv Microvascular Endothelial Cell medium
We look forward to hearing about how you’re using our new cardiac cells and new ways to use our culture media. Share your research and your study could be featured here on our blog